<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Reproductive Pharmacology</title>
    <meta name="author" content="Andy Vo">

    <link rel="stylesheet" href="repro_styles_7.css">
</head>

<body>
    <h1>Repro #7 - Reproductive Pharmacology</h1>
    <hr>
    <br>
    <div class="ToC">
        <b>Table of Content</b><br>
        <ol type="1" class="ToC">
            <li>Oral Contraceptives (OCP)</li>
            <li></li>
        </ol>
    </div>
    <br>
    <img src="img/repro_pharm.png" width="50%" alt="" style="margin: auto;">
    <br>

    <h2>Contraception</h2>
    <hr>
    <h3>Intrauterine Devices</h3>
    <h4>Copper-releasing IUD</h4>
    <table class="pharm">
        <tr>
            <td>MECHANISM OF ACTION</td>
            <td>Produces local inflammatory reaction toxic to sperm and ova, preventing fertilization and implantation<br>
                &#8627;&nbsp;reduce sperm function and motility<br>
                &#8627;&nbsp;disrupt normal division of oocytes and formation of fertilizable ovarian<br>
                &#8627;&nbsp;disrupt endometrium sufficiently to prevent implantation</td>
        </tr>
        <tr>
            <td>CLINICAL USE</td>
            <td>Long-acting reversible contraception. Most effective emergency contraception (up to 120 hrs/5 days following unprotected intercourse).<br>
                &#8627;&nbsp;failure rate: 0.7% in 1 year, 2.2% in 12 years<br>
                &#8627;&nbsp;lasts 10+ years
            </td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>Heavier or longer menses, dysmenorrhea. Risk of PID with insertion</td>
        </tr>
        <tr>
            <td>CONTRAINDICATIONS</td>
            <td>Active pelvic infection, pregnancy or suspected pregnancy, distorted uterine cavity, undx'd uterine bleeding, malignancy of genital tract, allergy to component (or Wilson's dz)</td>
        </tr>
    </table>
    <br>
    
    <h4>Levonorgestrel IUD (also hLARC)</h4>
    <i>Brand names:</i> Mirena, Liletta, Kyleena<br>
    <table class="pharm">
        <tr>
            <td>MECHANISM OF ACTION</td>
            <td>Releases 5-20 mcg levonorgestrel per day, <u>primarily local effects</u><br>
                &#8627;&nbsp;<b>sperm motility and function impaired</b><br>
                &#8627;&nbsp;cervical mucus thickened<br>
                &#8627;&nbsp;endometrium maintained in "resting" state<br>
                &#8627;&nbsp;ovulation inhibited only in some cycles<br>
                No estrogen
            </td>
        </tr>
        <tr>
            <td>CLINICAL USE</td>
            <td>Long-acting reversible contraception.<br>
                &#8627;&nbsp;failure rate: 0.1-0.8% per year<br>
                &#8627;&nbsp;lasts 5-6 years depending on brand
                Endometreial production for women receiving estrogen replacement (OFF-LABEL)
            </td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>Heavy menses</td>
        </tr>
        <tr>
            <td>CONTRAINDICATIONS</td>
            <td>Active pelvic infection, pregnancy or suspected pregnancy, distorted uterine cavity, undx'd uterine bleeding, malignancy of genital tract</td>
        </tr>
    </table>
    <br>
    
    <h3>Hormonal Long-acting Reversible Contraceptives (LARCs)</h3>
    <h4>Etonogestrel implant</h4>
    <i>Brand names:</i> Nexplanon<br>
    <table class="pharm">
        <tr>
            <td>MECHANISM OF ACTION</td>
            <td>Releases 20-60 mcg etonogestrel per day; suppresses ovluation, thicken cervical mucus, alters endometrium<br>
                No estrogen
            </td>
        </tr>
        <tr>
            <td>CLINICAL USE</td>
            <td>Long-acting reversible contraception.<br>
                &#8627;&nbsp;lasts for 3 years
            </td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>Menstrual irregularities</td>
        </tr>
        <tr>
            <td>CONTRAINDICATIONS</td>
            <td>same as other progestin-only methods*</td>
        </tr>
    </table>
    <br>

    <h3>Combined Hormonal Contraceptives</h3>
    <table class="pharm">
        <tr>
            <td>MECHANISM OF ACTION</td>
            <td>Progestins + ethinl estradiol; forms include pill, patch (Xulane), and intravaginal ring (NuvaRing)<br>
                &#8627;&nbsp;both inhibit LH/FSH and thus prevent estrogen surge. No estrogen surge &rarr; no LH surge &rarr; no ovulation.<br>
                &#8627;&nbsp;progestins causes thickening of mucus, thereby lmiting access of sperm to uterus.<br>
                &#8627;&nbsp;progesting also inhibit endometrial proliferation &rarr; less suitable for implantation
            </td>
        </tr>
        <tr>
            <td>CLINICAL USE</td>
            <td>Long-acting reversible contraception.<br>
            </td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>breakthrough menstrual bleeding, breast tenderness, VTE, hepatic adenomas</td>
        </tr>
        <tr>
            <td>CONTRAINDICATIONS</td>
            <td>smokers > 35 y/o, pts with &uarr; risk of CV dz, migrane (esp. w/ aura), breast cancer, liver cancer</td>
        </tr>
    </table>
    <br>

    <h3>Progestin-only Pills</h3>
    <i>Generics:</i> levonorgestrel, medroxyprogesterone, etonogestrel, norethinodrone, megestrol
    <table class="pharm">
        <tr>
            <td>MECHANISM OF ACTION</td>
            <td>Binds progesterone receptors, &darr; growth and &uarr; vascularization of endometrium, thicken cervical mucus</td>
        </tr>
        <tr>
            <td>CLINICAL USE</td>
            <td>Contraception (including pills, IUDs, implants [Nexplanon], and depot injection [DMPA])<br>
                endometreial cancer, abnormal uterine bleeding
            </td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>hypoesterogenism, breast tenderness, &uarr; appeptite & weight; acne (only w/o estrogen)<br>
                DMPA - loss of bone mineral density, teratogenesis
            </td>
        </tr>
        <tr>
            <td>CONTRAINDICATIONS</td>
            <td>Current breast cancer, known or suspected pregnancy, VTE, liver tumors, active liver dz, undiagnosed abnormal genital bleeding, known sensitivity to progestin</td>
        </tr>
    </table>
    
    <h2>Infertility Treatments</h2>
    <hr>
    <h3>Oral</h3>
    <h4>Clomiphenate citrate, letrozole</h4>

    <h3>Injectable</h3>
    <h4>Gonadotropins rFSH/LH/hCG SQ</h4>

    <h2>Pregnancy & Partum</h2>
    <hr>
    <h3>Prostaglandins - Cervical ripening</h3>
    <h4>Misoprostol (PGE1), dinoprostone (PGE2)</h4>

    <h3>Oxytocin - induction of labor</h3>

    <h3>Antifibrinolytic Agents (tranexamic acid) - post-partum hemorrhage</h3>
    <h3>Uterotonics - post-partum hemorrhage</h3>
    <h4>pitocin (oxyctocin), misoprostol</h4>

    <h3>Missed abortion</h3>
    <h4>Misoprostol +/- mifepristone</h4>
    

</body>
</html>